New combo therapy aims to beat leukemia without harsh chemo
NCT ID NCT07564453
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new treatment strategy for adults newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The approach combines a reduced-dose chemotherapy with a full course of the immunotherapy drug blinatumomab, and may also include CAR-T cell therapy or a stem cell transplant for some patients. The goal is to improve the chance of staying cancer-free for at least two years while reducing side effects. The study plans to enroll 101 people aged 15 to 65.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blinatumomab (an immunotherapy drug) combined with reduced-dose chemotherapy
- What this could lead to
- If successful, this approach could offer a more effective and less toxic first-line treatment for B-cell acute lymphoblastic leukemia, potentially improving long-term survival and reducing the need for intensive chemotherapy.
- What could go wrong
- This is a single-arm phase 2 trial with only 101 participants, so results may not be generalizable. The combination therapy may cause significant side effects, and the long-term benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Antibody combo beat a tough leukemia?
- New combo aims to wipe out hidden leukemia cells
- New combo therapy aims to deepen remissions in tough leukemia
- New Antibody-Drug combo aims to tackle tough leukemia
- New combo therapy aims to wipe out leukemia in adults who Can't take standard treatment
- New enzyme combo aims to boost leukemia treatment in High-Risk adults